|Calculated MW||This protein is fused with a human IgG1 Fc tag at C-terminus and has a calculated MW of 38.7 kDa. The protein migrates as 45-50 kDa in SDS-PAGE due to glycosylation.|
|Other Names||BTLA, CD272|
|Source||HEK 293 cells|
|Application Notes||Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml|
|Storage||-20°C;Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Normally Mannitol or Trehalose is added as protectants before lyophilization.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.